Molecular Therapy · 2014 · 202 citations · 44 references
Life SciencesImmunologyMolecular BiologyAntibody EngineeringCancer ImmunologyImmunotherapyAntigen RecognitionAntitumor T Cell ResponsesCancer ImmunotherapyCell-mediated ImmunityChimeric Antigen Receptor T-cell TherapyFc EngineeringAdaptive Antitumor ImmunityAntigen Recognition DomainsChimeric Antigen Receptor DesignFc ReceptorsImmune Cell EngraftmentOptimal DesignSpacer DesignT-cell Signaling Domains
The success of adoptive therapy using chimeric antigen receptor (CAR)–expressing T cells partly depends on optimal CAR design. CARs frequently incorporate a spacer/linker region based on the constant region of either IgG1 or IgG4 to connect extracellular ligand-binding with intracellular signaling domains. Here, we evaluated the potential for the IgG4-Fc linker to result in off-target interactions with Fc gamma receptors (FcγRs). As proof-of-principle, we focused on a CD19-specific scFv-IgG4-CD28-zeta CAR and found that, in contrast to CAR-negative cells, CAR+ T cells bound soluble FcγRs in vitro and did not engraft in NSG mice. We hypothesized that mutations to avoid FcγR binding would improve CAR+ T cell engraftment and antitumor efficacy. Thus, we generated CD19-specific CARs with IgG4-Fc spacers that had either been mutated at two sites (L235E; N297Q) within the CH2 region (CD19R(EQ)) or incorporated a CH2 deletion (CD19Rch2Δ). These mutations reduced binding to soluble FcγRs without altering the ability of the CAR to mediate antigen-specific lysis. Importantly, CD19R(EQ) and CD19Rch2Δ T cells exhibited improved persistence and more potent CD19-specific antilymphoma efficacy in NSG mice. Together, these studies suggest that optimal CAR function may require the elimination of cellular FcγR interactions to improve T cell persistence and antitumor responses. The success of adoptive therapy using chimeric antigen receptor (CAR)–expressing T cells partly depends on optimal CAR design. CARs frequently incorporate a spacer/linker region based on the constant region of either IgG1 or IgG4 to connect extracellular ligand-binding with intracellular signaling domains. Here, we evaluated the potential for the IgG4-Fc linker to result in off-target interactions with Fc gamma receptors (FcγRs). As proof-of-principle, we focused on a CD19-specific scFv-IgG4-CD28-zeta CAR and found that, in contrast to CAR-negative cells, CAR+ T cells bound soluble FcγRs in vitro and did not engraft in NSG mice. We hypothesized that mutations to avoid FcγR binding would improve CAR+ T cell engraftment and antitumor efficacy. Thus, we generated CD19-specific CARs with IgG4-Fc spacers that had either been mutated at two sites (L235E; N297Q) within the CH2 region (CD19R(EQ)) or incorporated a CH2 deletion (CD19Rch2Δ). These mutations reduced binding to soluble FcγRs without altering the ability of the CAR to mediate antigen-specific lysis. Importantly, CD19R(EQ) and CD19Rch2Δ T cells exhibited improved persistence and more potent CD19-specific antilymphoma efficacy in NSG mice. Together, these studies suggest that optimal CAR function may require the elimination of cellular FcγR interactions to improve T cell persistence and antitumor responses.
44
A human memory T cell subset with stem cell–like properties
Luca Gattinoni, Enrico Lugli, Yun Ji et al. · Nature Medicine · 2011 · 1.9K citations · Full text
Leonard D. Shultz, Bonnie Lyons, Lisa Burzenski et al. · The Journal of Immunology · 2005 · 1.7K citations · Full text
NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells
Mamoru Ito, Hidefumi Hiramatsu, Kimio Kobayashi et al. · Blood · 2002 · 1.5K citations
Michael C. Milone, Jonathan D. Fish, Carmine Carpenito et al. · Molecular Therapy · 2009 · 1.2K citations · Full text
Life Sciences, Immunology, Oncology +17